Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
© The Author(s) 2023. Published by Oxford University Press..
INTRODUCTION: Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored.
METHODS: Microbiome was analyzed by 16SrRNA sequencing.
RESULTS: Twenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time.
CONCLUSIONS: Fecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
The oncologist - 28(2023), 9 vom: 07. Sept., Seite e703-e711 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vernaci, Grazia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anthracyclines |
|---|
| Anmerkungen: |
Date Completed 11.09.2023 Date Revised 10.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/oncolo/oyad060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354456679 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354456679 | ||
| 003 | DE-627 | ||
| 005 | 20231226062248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/oncolo/oyad060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354456679 | ||
| 035 | |a (NLM)36940301 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vernaci, Grazia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.09.2023 | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press. | ||
| 520 | |a INTRODUCTION: Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a better event-free survival. The role of gut microbiome in early TNBC is underexplored | ||
| 520 | |a METHODS: Microbiome was analyzed by 16SrRNA sequencing | ||
| 520 | |a RESULTS: Twenty-five patients with TNBC treated with neoadjuvant anthracycline/taxane-based chemotherapy were included. Fifty-six percent achieved a pCR. Fecal samples were collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 samples (90.7%) were suitable for microbiome analysis. At t0, pCR group showed a significantly higher α-diversity as compared with no-pCR, (P = .049). The PERMANOVA test on β-diversity highlighted a significant difference in terms of BMI (P = 0.039). Among patients with available matched samples at t0 and t1, no significant variation in microbiome composition was reported over time | ||
| 520 | |a CONCLUSIONS: Fecal microbiome analysis in early TNBC is feasible and deserves further investigation in order to unravel its complex correlation with immunity and cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a TNBC | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a microbiome | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 700 | 1 | |a Savarino, Edoardo Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Patuzzi, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Facchin, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Zingone, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Massa, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Faggioni, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Giarratano, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Miglietta, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Griguolo, Gaia |e verfasserin |4 aut | |
| 700 | 1 | |a Fassan, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Mele, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Gasparini, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bisagni, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Guarneri, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Dieci, Maria Vittoria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d 1998 |g 28(2023), 9 vom: 07. Sept., Seite e703-e711 |w (DE-627)NLM095483306 |x 1549-490X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:9 |g day:07 |g month:09 |g pages:e703-e711 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/oncolo/oyad060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 9 |b 07 |c 09 |h e703-e711 | ||